Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

• Author(s): Veiga, Viviane C. ; Prats, João A. G. G. ; Farias, Danielle L. C. ; Rosa, Regis G. ; Dourado, Leticia K. ; Zampieri, Fernando G. ; Machado, Flávia R. ; Lopes, Renato D. ; Berwanger, Otavio ; Azevedo, Luciano C. P. ; Avezum, Álvaro ; Lisboa, Thiago ; Rojas, Salomón S. O. ; Coelho, Juliana C. ; Leite, Rodrigo T. ; Carvalho, Júlio C. ; Andrade, Luis E. C. ; Sandes, Alex F. ; Pintão, Maria C. T. ; Castro Junior, Claudio G. ; Santos, Sueli V. ; de Almeida, Thiago M. L. ; Costa, André N. ; Gebara, Otávio C. E. ; Freitas, Flávio G. Rezende de ; Pacheco, Eduardo S. ; Machado, David J. B. ; Martin, Josiane ; Conceição, Fábio G. ; Siqueira, Suellen R. R. ; Damiani, Lucas P. ; Ishihara, Luciana M. ; Schneider, Daniel ; Souza, Denise de ; Cavalcanti, Alexandre B. ; Scheinberg, Phillip
• Date: 2021
• Persistent ID: VEIGA, V. C. et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, v. 372, n. 84, jun. 2021. Disponível em: http://hdl.handle.net/11690/1780. Acesso em: 08 jul. 2021.
• Origin: Oasisbr
• Subject(s): COVID-19
• Document Type: Journal article
• Language: English

Description

Submitted by DSpace Unilasalle ([e-mail]) on 2021-07-08T19:57:41Z No. of bitstreams: 1 Effect Tocilizumab_BMJ.pdf: 431355 bytes, checksum: 83c2f6347869beeb8527bbcf4a8a36c5 (MD5)

Made available in DSpace on 2021-07-08T19:57:41Z (GMT). No. of bitstreams: 1 Effect Tocilizumab_BMJ.pdf: 431355 bytes, checksum: 83c2f6347869beeb8527bbcf4a8a36c5 (MD5) Previous issue date: 2021